Part 1 : To evaluate the safety of single-dose KK3910 in healthy volunteers. Part 2 : To evaluate the safety of multiple-dose KK3910 in patients with essential hypertension.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
144
Kitasato University Kitasato Institute Hospital
Minato-ku, Tokyo, Japan
RECRUITINGNumber of participants with adverse events (AEs)
For adverse events that occurred after administration of the investigational drug, number of subjects with AEs and occurrence frequency are evaluated.
Time frame: Part 1 : Day 1 to Day 85, Part 2: Day 1 to Day 155
Time to the maximum concentration
Time frame: Part 1 : Day 1 to Day 85, Part 2 : Day 1 to Day 155
The maximum concentration
Time frame: Part 1 : Day 1 to Day 85, Part 2 : Day 1 to Day 155
Area under the concentration-Time curve
Time frame: Part 1 : Day 1 to Day 85, Part 2 : Day 1 to Day 155
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.